A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma.

[1]  A. Reuss,et al.  Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  U. Neumann,et al.  Clinical outcome of patients with advanced ovarian cancer after resection of liver metastases. , 2012, Anticancer research.

[3]  R. Coleman,et al.  Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer , 2011, Drugs.

[4]  M. Kris,et al.  Targeting Lewis Y (Ley) in Small Cell Lung Cancer with a Humanized Monoclonal Antibody, hu3S193: A Pilot Trial Testing Two Dose Levels , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  A. Scott,et al.  A Phase I Biodistribution and Pharmacokinetic Trial of Humanized Monoclonal Antibody Hu3s193 in Patients with Advanced Epithelial Cancers that Express the Lewis-Y Antigen , 2007, Clinical Cancer Research.

[6]  P. Sabbatini.  New agents and new formulations for the treatment of ovarian cancer. , 2005, Clinical advances in hematology & oncology : H&O.

[7]  E. Eisenhauer,et al.  Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer) , 2005 .

[8]  M. Cronk,et al.  Case report of a generalized seizure related to Paclitaxel infusion. , 2004, Journal of the National Cancer Institute.

[9]  A. Scott,et al.  Generation of anti-idiotype antibodies for application in clinical immunotherapy laboratory analyses. , 2003, Hybridoma and hybridomics.

[10]  L. Old,et al.  Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. , 2001, Cancer research.

[11]  D Guthrie,et al.  Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Scott,et al.  Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. , 2000, Cancer research.

[13]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[14]  M. Bookman,et al.  Second-line treatment of ovarian cancer. , 2000, The oncologist.

[15]  D. Smith,et al.  High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  B. Yin,et al.  Serological and immunochemical analysis of Lewis Y (Ley) blood group antigen expression in epithelial ovarian cancer , 1996, International journal of cancer.

[17]  L. Old,et al.  Specificity analysis of blood group Lewis-y (Le(y)) antibodies generatedagainst synthetic and natural Le(y) determinants. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[18]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[19]  N. Hacker,et al.  Distant metastases in epithelial ovarian carcinoma , 1987, Cancer.

[20]  C. Cordon-Cardo,et al.  Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines. , 1986, Cancer research.

[21]  A. Jemal,et al.  Global Cancer Statistics , 2011 .